Stayveer

Stayveer is used to treat patients with class III pulmonary arterial hypertension (PAH) to improve exercise capacity (the ability to carry out physical activity) and reduce symptoms. PAH is abnormally high blood pressure in the arteries of the lungs. The ‘class’ reflects the severity of the disease: ‘class III’ PAH involves marked limitation of physical activity. The PAH can be: - primary (with no identified cause or inherited); - caused by scleroderma (also called systemic sclerosis, a disease where there is abnormal growth of the connective tissue that supports the skin and other organs); - caused by congenital (inborn) heart defects with shunts (abnormal passageways) causing abnormal flow of blood through the heart and Some improvement with Stayveer can also occur in patients with class II PAH. ‘Class II’ involves slight limitation of physical activity. Stayveer can also be used in adults with systemic sclerosis in whom poor blood circulation caused by the disease has led to the development of digital ulcers (sores on the fingers and toes). Stayveer is given to reduce the number of new digital ulcers. Stayveer contains the active substance bosentan. This medicine is the same as Tracleer, which is already authorised in the EU. The company that makes Tracleer has agreed that its scientific data can be used for Stayveer (‘informed consent’).